Andere Sprachen Alimera Sciences, Inc.

Aktien

A2PVHE

US0162592028

ALIM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 06.05.2024			% 5 Tage	% 1. Jan.
3,75 ^USD	+2,74 %		+2,18 %	-13,19 %

25.03.	ALIMERA SCIENCES, INC. : Maxim bekräftigt seine Kaufempfehlung	ZM
19.03.	Alimera Sciences, Inc. gibt bekannt, dass der erste Patient in die vom DRCR Retina Network durchgeführte Studie zur Strahlenretinopathie randomisiert wurde	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update	30.04.
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20.03.
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	19.03.
Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	19.03.
Alimera Sciences: Q4 Earnings Snapshot	07.03.
Alimera Sciences, Inc. Enters into the Seventh Amendment to Its Loan and Security Agreement	07.03.
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	07.03.
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	07.03.
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results	07.03.
Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024	07.03.
Alimera Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Alimera Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07.03.
North American Morning Briefing : Powell Still in -2-	07.03.
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update	29.02.
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®	08.02.
Alimera Completes Recruitment for the Synchronicity Study	04.01.
Alimera Completes Recruitment for the Synchronicity Study	04.01.
Alimera Sciences Appoints New CFO	02.01.
Alimera Sciences, Inc. Names Elliot Maltz as Chief Financial Officer	02.01.
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	02.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alimera Sciences, Inc.

Aktien

A2PVHE

US0162592028

ALIM

Andere Sprachen

Filter